We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03155802
Recruitment Status : Unknown
Verified October 2019 by Stony Brook University.
Recruitment status was:  Recruiting
First Posted : May 16, 2017
Last Update Posted : November 1, 2019
Sponsor:
Collaborator:
Gilead Sciences
Information provided by (Responsible Party):
Stony Brook University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a pilot prospective cohort study, in adult female subjects 18-85 years old with a diagnosis of invasive breast cancer who are planned for anthracycline-inclusive chemotherapy and followed up for a time period of 6 months post completion of anthracycline chemotherapy. They will participate in blood and imaging tests with a goal of determining the best method for predicting the occurrence of cardiotoxicity in this subpopulation.

Condition or disease
Cardiotoxicity Heart Failure Breast Cancer Anthracycline Induced Cardiomyopathy Biomarkers Echocardiography

Detailed Description:

Anthracyclines and other chemotherapy agents are associated with cardiotoxicity. The risk of cardiac related toxicity is increased in patients with advanced age, with multiple comorbid conditions, and those needing prolonged or intensive treatment. These patients require a tailored approach to surveillance, early diagnosis and treatment of cardiac issues related to cancer therapy, with timely decision making with respect to alterations in therapy. A serum biomarker approach alone or in combination with imaging indices holds promise for early identification, risk stratification and monitoring of chemotherapy related cardiotoxicity.

Thirty-five consecutive adult females between the ages of 18-85 with diagnosis of invasive breast cancer, planned for anthracycline inclusive chemotherapy (+/- taxanes, +/- trastuzumab) will be enrolled.

A detailed medical history (interim where appropriate), physical exam, collection of blood samples for the measurement of Heart Failure (HF) biomarkers (and standard chemistry and hematology parameters), electrocardiogram and a 2D/3D echo cardiogram including the measurement of global longitudinal strain will be performed at baseline, mid chemotherapy, at the end of chemotherapy and 6 months post the completion of chemotherapy. (echocardiogram will not be done during chemotherapy).

The hypothesis being tested in this prospective trial is whether early changes in the levels of serum biomarkers of stress (N terminal pro B-type natriuretic peptide (NT-proBNP)), inflammation (ST2), necrosis (hs troponin), and fibrosis (galectin-3) will correlate with changes in sub-clinical left ventricular dysfunction as assessed by 3-dimensional (3D) echocardiogram with speckle tracking/strain in breast cancer patients receiving anthracycline based chemotherapy.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 35 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Use of Novel Biomarkers and Echocardiography to Assess Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines
Actual Study Start Date : April 18, 2017
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Association of Heart Failure Biomarkers with Global Longitudinal strain rate [ Time Frame: up to 35 weeks ]
    N Terminal-proBNP, hs troponin, ST2, galectin-3 with global longitudinal strain rate


Secondary Outcome Measures :
  1. Prediction of initiation/change in cardiovascular medications based on serum biomarkers [ Time Frame: up to 35 weeks ]
    NT-proBNP

  2. Prediction of initiation/change in cardiovascular medications based on serum biomarkers [ Time Frame: up to 35 weeks ]
    ST2

  3. Prediction of initiation/change in cardiovascular medications based on serum biomarkers [ Time Frame: up to 35 weeks ]
    hs-troponin

  4. Prediction of initiation/change in cardiovascular medications based on serum biomarkers [ Time Frame: up to 35 weeks ]
    galectin-3

  5. Prediction of cardiotoxicity based on serum biomarkers [ Time Frame: up to 35 weeks ]
    galectin-3

  6. Prediction of cardiotoxicity based on serum biomarkers [ Time Frame: up to 35 weeks ]
    NT-proBNP

  7. Prediction of cardiotoxicity based on serum biomarkers [ Time Frame: up to 35 weeks ]
    hs-troponin

  8. Prediction of cardiotoxicity based on serum biomarkers [ Time Frame: up to 35 weeks ]
    ST2


Other Outcome Measures:
  1. Association between modifications in chemotherapy with detection of subclinical cardiotoxicity [ Time Frame: up to 10 weeks ]
    frequency of chemotherapy changes with subclinical cardiotoxicity


Biospecimen Retention:   Samples Without DNA
Serum will be kept at -70 degrees of Celsius for future research

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
females between the ages of 18-85 with diagnosis of invasive breast cancer, planned for anthracycline inclusive chemotherapy (+/- taxanes, +/- trastuzumab).
Criteria

Inclusion Criteria:

  1. Female subjects aged 18-85 years old
  2. Biopsy-proven diagnosis of invasive breast cancer carcinoma
  3. Plan for anthracycline inclusive chemotherapy (+/- taxanes, +/- trastuzumab)

Exclusion Criteria:

  1. History of major heart disease at the time of breast cancer diagnosis (myocardial infarction or known left ventricular dysfunction (LVD) at baseline (defined as ejection fraction <40%)
  2. History of known obstructive coronary artery disease (CAD), or coronary revascularization within the past 1 year
  3. History of clinical heart failure or previous heart failure hospitalization
  4. Patients with elevations in NT-pro BNP (above 3x ULN), or ST2 (above 2x ULN), galectin-3 (above 2x ULN), or hs troponin (above 2x ULN) during baseline screening
  5. Patients with metastatic disease or recurrent breast cancer at diagnosis
  6. History of other chemotherapy treated malignancy
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03155802


Contacts
Layout table for location contacts
Contact: Michelle Bloom, MD 6314442031 michelle.bloom@stonybrookmedicine.edu
Contact: Indre Caikauskaite 6314442031 indre.caikauskaite@stonybrookmedicine.edu

Locations
Layout table for location information
United States, New York
Stony Brook Medicine Recruiting
Stony Brook, New York, United States, 11738
Contact: Michelle Bloom, MD    631-444-2031    michelle.bloom@stonybrookmedicine.edu   
Sponsors and Collaborators
Stony Brook University
Gilead Sciences
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Stony Brook University
ClinicalTrials.gov Identifier: NCT03155802    
Other Study ID Numbers: 922042
First Posted: May 16, 2017    Key Record Dates
Last Update Posted: November 1, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Cardiomyopathies
Cardiotoxicity
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
 Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Radiation Injuries
Wounds and Injuries